# MB-CART2019.1 in Refractory Multiple Sclerosis

> **NCT07178431** · PHASE1,PHASE2 · RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 26 (estimated)

## Conditions studied

- Multiple Sclerosis
- CAR T Cell Therapy

## Interventions

- **BIOLOGICAL:** MB-CART2019.1

## Key facts

- **NCT ID:** NCT07178431
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-08-16
- **Final completion:** 2030-08-16
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178431, "MB-CART2019.1 in Refractory Multiple Sclerosis". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07178431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*